Journal: Diabetes, Obesity & Metabolism
Article Title: Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar Insulin 70/30 with US ‐licensed HUMULIN® 70/30 formulation in healthy subjects: Results from the RHINE ‐3 ( R ecombinant H uman IN sulin E quivalence‐3) study
doi: 10.1111/dom.14768
Figure Lengend Snippet: Mean GIR profiles (PPP for PD). Two profiles each receiving Biocon's Insulin‐70/30 and HUMULIN 70/30 were excluded from the PPP (n = 72) for PD based on C‐peptide exclusion rules and during the blinded database release meeting (because of extended gaps in continuous glucose monitoring), respectively. GIR, glucose infusion rates; PD, pharmacodynamics; PPP, per‐protocol population
Article Snippet: GIR max and other time‐related PD parameters were calculated from smoothed GIR profiles (SAS procedure PROC LOESS with smoothing factor 0.25).
Techniques: Drug discovery